

# Staging Laparoscopy Is Still a Valuable Tool for Optimal Gastric Cancer Management

Erica Sakamoto (✉ [erica.sak@gmail.com](mailto:erica.sak@gmail.com))

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas <https://orcid.org/0000-0002-0845-0730>

Marcus Fernando Kodama Pertille Ramos

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

Marina Alessandra Pereira

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

Andre Roncon Dias

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

Ulysses Ribeiro Junior MD

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

Bruno Zilberstein

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

Sergio Carlos Nahas

HCFMUSP: Universidade de Sao Paulo Hospital das Clinicas

---

## Research Article

**Keywords:** Stomach Neoplasms, Laparoscopy, Neoplasm Staging, Peritoneal Neoplasms

**Posted Date:** February 24th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-253611/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Purpose:** Complete surgical resection is the main determining factor in the survival of advanced gastric cancer (AGC) patients, but resection should be avoided in metastatic disease. Peritoneum is a common site of metastasis and preoperative imaging techniques still fail to detect peritoneal metastasis (PM). Thus, the aim of this study was to evaluate the role of Staging Laparoscopy (SL) in the staging of AGC patients in a Western tertiary cancer center.

**Methods:** We reviewed 130 patients with gastric adenocarcinoma submitted to SL from 2009 to 2020 from a prospective database. Clinicopathological characteristics were analyzed to identify factors associated with the presence of PM. We also evaluated the accuracy and strength of agreement between computed tomography (CT) and SL in detecting PM, and the change in treatment strategy after SL.

**Results:** Among the 130 patients, PM was identified in 66 patients (50.76%) - P1 group. The sensitivity, specificity and accuracy of CT in detecting PM were 51.5%, 87.5% and 69.2%, respectively. According to the Kappa coefficient, concordance between SL and CT was 38.8%. In multivariate analysis, ascites ( $p=0.001$ ) and suspected PM on CT scan ( $p=0.007$ ) were statistically correlated with the P1 group. In 40 patients (30.8%), staging and treatment plans changed after SL (32 patients avoided unnecessary laparotomy and 8 patients who were previously considered stage IVb by CT scan were referred for surgical treatment).

**Conclusions:** Even with current advances in imaging techniques, SL demonstrated an important role in the diagnosis of PM and remains valuable for determining the correct therapeutic strategy.

## Introduction

Gastric cancer (GC) is the third leading cause of death in the world.[1] The high incidence rates of GC in East Asian countries led to the adoption of screening strategies such as upper digestive endoscopy, which results in early diagnosis. On the other hand, in Western countries, most cases are diagnosed in advanced stages. In Brazil, patients with advanced disease represent around 85% of all GC cases.[2]

Surgery remains the main curative treatment option for advanced gastric cancer (AGC), and gastrectomy with D2 lymphadenectomy is the standard surgical treatment. However, approximately 15% of patients have peritoneal metastasis (PM) at diagnosis.[3, 4]

Clinical staging includes upper digestive endoscopy and computed tomography (CT) scan of the chest, abdomen, and pelvis. However, the accuracy of CT scan to diagnose PM is low.[5] Previous studies have demonstrated that CT sensitivity for detecting PM ranges from 14 to 59%.[6] In many cases, PM is only detected during laparotomy, making the indication of gastrectomy questionable. In these situations, chemotherapy is the standard treatment if the patients are asymptomatic. REGATTA trial demonstrated that surgical resection followed by chemotherapy does not provide any survival benefit for incurable AGC

compared with palliative chemotherapy alone.[7] Thus, surgical resection in those cases only adds risks of post-surgical complications and delays the onset of chemotherapy.[8]

Staging laparoscopy (SL) in GC was introduced in the early 1980s.[9] It allows detailed inspection of the entire peritoneal surface, collection of oncotic cytology, identification of suspicious lesions and biopsies. It can be used both to confirm suspected peritoneal lesions on imaging studies and to rule out carcinomatosis prior to neoadjuvant treatment.[8, 10, 11] Several studies have demonstrated its superiority regarding conventional imaging tests to detect PM. Additionally, SL is a low-invasive treatment with a low risk of postoperative complications.[12, 13]

However, some discrepancies regarding which patients it should be performed and its importance in defining the therapeutic approach are still subject of discussion. Thus, the aim of this study was to evaluate the role of SL in the staging of GC patients in a single Western tertiary cancer center. Additionally, we evaluated the accuracy of SL in relation to CT scan findings.

## Materials And Methods

We reviewed all patients with GC submitted to SL from 2009 to 2020 from a prospective database. Only patients with gastric adenocarcinoma were included. Indications for SL were AGC (T3, T4), suspected peritoneal lesions and staging prior to neoadjuvant chemotherapy. Laparoscopies performed for other purposes such as inflammatory acute abdomen, evaluation for recurrence and resectability after chemotherapy were excluded.

Patients were staged preoperatively through abdominal and pelvis CT scan, upper digestive endoscopy, and laboratory tests. Clinical characteristics evaluated included age, sex, BMI (body mass index), preoperative laboratory tests (serum hemoglobin, serum albumin, Neutrophil-Lymphocyte Ratio-NLR[14]), presence of comorbidities – using Charlson Comorbidity Index (CCI)[15] and American Society of Anesthesiologists (ASA) classification.[16]

Location of the tumor (classified as cardia, fundus, body, antrum or whole stomach), macroscopic configuration (using the JGCA classification, which is based on Borrmann's classification) and tumor size were assessed by endoscopic examination.

CT radiological reports were used for tumor staging. CT criteria for staging was based on previous studies[17–19] and included the following parameters according to the TNM 8th edition:[20]

- For depth invasion (T):

T1: Focal thickening/enhancement of the inner layer

T2: Complete thickening of the gastric wall, with loss or disruption of a low-attenuation stripe at the base of the lesion, but a clear and well defined outer gastric surface

T3: Complete thickening of the gastric wall, with **visually** impossible discrimination between the gastric lesion and the outer layer, perigastric fat tissue preserved.

T4a: Complete thickening of the gastric wall, with irregular or nodular outer layer and perigastric fat infiltration.

T4b: Infiltration of adjacent organs.

- Lymph nodes of greater size than 10 mm in the short axis diameter were considered malignant and recorded as absent or present.
- Presence of ascites, signs suggestive of PM (including peritoneal thickening/enhancement, peritoneal nodules or presence of omental cake), liver metastasis or distant lymph node metastasis (retropancreatic, pancreaticoduodenal, peripancreatic, superior mesenteric, middle colic, para-aortic, or retroperitoneal node) were evaluated.

The postoperative follow-up was performed quarterly in the first year and every six months in the following years. Follow-up tests for relapse detection were based on the presence of symptoms. Absence in appointments for more than 12 months was considered as loss of follow-up. All cases were operated in a high-volume center by specialized surgeons.

The study was approved by the Hospital's Ethics Committee and registered online (<https://plataformabrasil.saude.gov.br>, CAAE 25512819.1.0000.0065).

## **Staging Laparoscopy**

SL was performed according to the standard technique used at our institution with the patient under general anesthesia. The first 10 mm trocar was placed in the supraumbilical region and a 12 mmHg pneumoperitoneum was established. Two 5 mm trocars were placed in the right and left lateral abdomen. The peritoneal cavity was inspected with careful investigation of the stomach surface, liver, diaphragm, peritoneum, omentum, mesentery, small bowel, and pelvic organs. The omental bursa was also inspected in cases of high suspicion of involvement (tumors located on the posterior wall of the stomach). Biopsies were performed for suspicious lesions and sent for pathological examination.

## **Statistical analysis**

The Chi-square tests were used for categorical variables and t-tests for continuous variables. The association of clinical characteristics with the diagnosis of peritoneal carcinomatosis by SL was analyzed by binary logistic regression analysis, and odds ratios (ORs) with a 95% confidence interval (95% CI) were calculated. Significant variables were included in the multivariate model.

The agreement between SL and CT was evaluated using the Kappa statistic. The Kappa coefficient was interpreted according to the Landis and Koch criteria,[21] classified as: poor (<1%), slight (1-20%), fair (21-40%), moderate (41- 60%), substantial (61-80%), almost perfect (81-100%).

Overall survival (OS) was estimated using the method of Kaplan–Meier, and differences in survival were examined using the Log Rank Test. Survival time (months) was calculated from the date of surgery until the date of death. The patients alive were censored at the date of the last contact. All tests were two-tailed, and  $p<0.05$  was considered statistically significant. The analysis was performed using SPSS software, version 18.0 (SPSS Inc, Chicago, IL).

## Results

### Clinicopathological characteristics

In the study period, a total of 130 GC patients who underwent SL were included in this study. The mean age was 59.6 years (range 24-86), with a mean BMI of 22.5 Kg/m<sup>2</sup> and male predominance (63,1%). The majority of patients had cT4 (80%) lesions, positive LN metastasis (85.5%) and had no suspected distant metastasis (64.6%). The characteristics of the patients are presented in **Supplementary Table(Online Resource 1)**.

Based on the SL result, patients were divided into two groups: P1 group, represented by 66 patients (50.76%) with evidence of peritoneal disease, and P0 group, represented by 64 patients (49.23%) with no evidence of peritoneal disease.

Clinical and pathological characteristics according to the diagnosis of carcinomatosis (P1 and P0 groups) are presented in **Table 1**. Patients in the P1 group were more likely to have circumferential tumors ( $p=0.005$ ), *linitis plastica* ( $p=0.001$ ) and to be classified as Lauren's diffuse type ( $p=0.001$ ). Tumor stenosis was observed in 25% and 30.3% of patients in P0 and P1 groups, respectively ( $p=0.499$ ). Three patients (4.7%) in the P0 group and 5 patients (7.6%) in the P1 group had remnant gastric cancer ( $p=0.493$ ). There were no differences in age, sex, BMI, presence of comorbidities and laboratory tests between groups.

### CT staging and imaging analysis

The majority of patients in both groups (P0 and P1) was classified as cT4 and had positive lymph node metastasis (cN+). **Table 2** presents CT scan findings (TNM staging, presence of ascites, signs suggestive of PM, liver metastasis or lymph node involvement) stratified by peritoneal disease status. Presence of PM, ascites and stage cIVb on CT scan were associated with P1 ( $p<0.05$ ). Neither lymph node nor liver metastasis was significantly associated with P1.

### Accuracy and strength of agreement between CT and SL in detecting PM

Of the 130 patients who underwent SL, 42 were classified by CT as positive for PM (P1 CT). Among them, 34 confirmed PM on subsequent SL (positive predictive value - PPV 81%).

In the remaining 88 patients classified by CT as negative for PM (P0 CT), SL confirmed absence of PM in 56 patients (negative predictive value - NPV 63.6%).

The sensitivity, specificity, and diagnostic accuracy calculations for CT detection of PM are presented in **Table 3**. Using SL results as reference, the sensitivity and specificity of CT were 51,5% and 87,5%, respectively. According to the Kappa coefficient, concordance between SL and CT in the diagnosis of carcinomatosis was 38.8%.

The analysis of risk factors for the diagnosis of carcinomatosis by SL demonstrated that ascites ( $p=0.001$ ) and suspected PM on CT scan ( $p=0.007$ ) were statistically correlated with the P1 group in multivariate analysis. (**Table 4**)

### **SL and treatment decision making**

Among the 130 patients who underwent SL, 88 patients (67.7%) had no signs of PM on CT scan (P0 CT). Of these patients, 32 (24.6%) were found to have positive occult peritoneal metastatic disease on SL and were able to avoid unnecessary laparotomy. On the other hand, of the 42 patients (32.3%) who had suspected PM on CT scan (P1 CT), SL excluded PM in 8 patients (6.15%). Thus, in 40 patients (30.8%), staging and treatment plans changed after SL.

### **Treatment after SL**

Of the 64 Of patients classified as P0 after SL, 51 (79.6%) were referred for Neoadjuvant Chemotherapy and 7 patients (10.9%) for upfront surgery. In total, 43 (67.1%) patients underwent surgical treatment. Thirty-one patients (48.4%) underwent gastrectomy with curative intent, and in two patients the anatomopathological results of the surgical specimen revealed PM. Another 12 (18.7%) patients had criteria for non-resectability in the second surgery and underwent palliative surgery (six patients due to PM and six patients due to invasion of adjacent structures). A total of 8 (12.5%) patients had PM at the second surgery.

### **Overall survival**

When comparing GC patients according to the M status by SL (M1 SL vs M0 SL), the survival of patients with peritoneal carcinomatosis was significantly worse than those without carcinomatosis (7.5 vs 16.5 months,  $p<0.001$ ).

When comparing M0 GC according to the method of staging, the mean OS for M0 patients who underwent SL was superior than patients who did not (16.5 vs 14 months) but without significance ( $p=0.121$ ).

## Discussion

Although surgery represents the cornerstone of AGC treatment, it is mainly indicated in the absence of metastatic disease. Despite the proven value of SL in the diagnosis of PM, there is no consensus yet on its routine use in clinical practice, and it remains underutilized in the management of GC, with reported frequencies of less than 25%.[\[22–26\]](#) Thus, the present study was developed to further address this issue and to highlight the importance of SL in the diagnosis of PM and treatment strategy. In our study, of the 130 patients submitted to SL, PM was found in 66 (50.76%). Additionally, our results regarding the accuracy of CT scan were consistent with previous studies and confirmed its limitations in detecting PM, with 51.5% of sensitivity, 87.5% of specificity and 69.2% of accuracy.

Even with technological advances in imaging diagnostics, SL still provides a superior ability to inspect the peritoneal surface. Currently, several guidelines include its use in staging.[\[27–29\]](#) The main objective is to detect occult PM and other factors that can change the therapeutic strategy, such as the invasion of adjacent structures and liver metastasis.[\[8\]](#) However, the appropriate selection of patients who are candidates for SL is still controversial and differs among various institutions. Some recommend it for all resectable GC (stage IB–III), especially for those who are being considered for neoadjuvant treatment.[\[28\]](#)

Based on previous literature, it is difficult to define the most appropriate indications for SL, notably due to the differences in studied populations and inclusion criteria. In Western series, where most cases are diagnosed in advanced stages, the tendency was to perform it in all patients with AGC. While in Eastern series, where most patients present with early-stage disease, the recommendation was to perform it selectively in individuals at high risk for PM.[\[12, 30, 31\]](#) A systematic review carried out by Fukugawa et al. found that, in Japanese institutions, SL evidenced positive findings in 42.7% to 53.4% of the cases, higher than in other countries (7.8% to 40%). This discrepancy was partly because they had a greater selection of patients at risk for PM.[\[8\]](#) In our study, PM was found in 66 patients (50.8%) submitted to SL, which is also a higher number compared to previous studies, mainly due to the same selection bias of high risk cases.

Some factors are known to increase the poor prognosis of GC and to be related to the presence of PM, as large Bormann type 3 and Bormann type 4.[\[13, 32–34\]](#) In a prospective cohort study, with pre-specified indications for SL, Irino et al. found a greater impact, achieving accuracy of 91.5%. Their indications were: large  $\geq 8$ cm Bormann type 3, Bormann type 4, bulky lymph nodes or paraaortic lymph node involvement and suspicion of PM on CT scan.[\[12\]](#) In our study, presence of ascites ( $p=0.001$ ) and suspected PM on CT scan ( $p=0.007$ ), were independent risk factors for PM (P1 group), suggesting that patients with these characteristics should always be considered for SL.

In previous systematic review, the use of SL provided a benefit by changing the treatment in 8.5–59.6% of cases, sparing patients from unnecessary laparotomy in 8.5–43.8% of cases.[\[25\]](#) These discrepancies are also partly due to the fact that the studies used different indications for performing SL. Our study revealed a considerably high percentage of therapeutic strategy change after SL (30.8%), sparing

laparotomy in 24,6% of the cases and offering surgery to 6,1% of the patients who were previously considered stage IVb by CT scan.

Difficulties related to the widespread adoption of SL are related to cost, and its invasive risk-prone procedure.[13, 14, 35–37]. Increasingly restricted availability of scheduling in the operating rooms for a procedure that requires general anesthesia may also play a role. Regarding the cost-effectiveness of SL, Kevin et al. (2017) reported that the expected benefit from avoiding unnecessary laparotomies may be low compared to the cost of routine use of SL. Nevertheless, it can be good if the procedure yield is high, especially in those with a high risk of occult PM suggesting a more selective practice.[37]

When comparing survival rates of patients who underwent SL to those staged by tomography, a difference was observed in the survival curves of M0 patients by tomography versus M0 patients by SL. Despite the absence of statistical significance, this could represent the impact of under-staging of CT scan on prognosis. Better selection of patients who are candidates for curative treatment is achieved with SL and some patients considered M0 by tomography could show occult carcinomatosis, and consequently worse prognosis and survival. A more significant number of patients should be studied to assess the statistical difference between the groups.

Despite the high accuracy of SL, of the 64 patients classified as P0 by SL, 8 (12.5%) patients presented with PM during the second surgery. Some authors reported this outcome as “false negative for SL”, with rates ranging from 0% to 17.2%.[8, 12, 32, 33, 38] While this corresponds to a failure of SL, it could also represent a disease progression between SL and the second surgery. The answer, however, remains unknown.

Our study had some limitations. First, being a retrospective study it carries an inherent selection bias in indicating patients with a greater suspicion of PM for SL. Additionally, we do not perform second SL after neoadjuvant chemotherapy. Thus, the percentage of change of conduct is higher than that found in some other studies. Also, we did not include in the study the evaluation of peritoneal lavage by cytology, since we do not have the results available for all patients. In addition, in our service, the evaluation of peritoneal lavage is performed using cytological and immunohistochemical techniques. Until now, molecular techniques such as RT-PCR for investigating tumor cells in the lavage are not part of our diagnostic routine. Indeed, previous studies have demonstrated improvements in the sensitivity of peritoneal washing using molecular diagnosis via reverse transcription-polymerase chain reaction (RT-PCR), being also useful for predicting the peritoneal recurrence and prognosis.[39, 40]

Notwithstanding the limitations, our study has also important strengths. It represents a 11-year period Western tertiary single-center experience. Our findings demonstrated that SL had a significant impact in GC staging, especially in the diagnosis of PM, along with its superiority regarding conventional imaging tests. Patients with peritoneal spread still represent a major challenge in oncology. Currently, clinical researches related to effective strategies to improve long-term survival are underway and novel intraperitoneal chemotherapies have emerged as potential treatment options.[41, 42] According to this

perspective, recognizing patients with metastasis limited only to the peritoneum, becomes even more important for best management.[43, 44]

## Conclusion

SL demonstrated an important role in the diagnosis of PM, contributing to the choice of the correct therapeutic strategy for the treatment of AGC. It should be considered for all advanced gastric tumors, particularly in the presence of ascites and suspected PM on CT scan.

## Declarations

### Funding

No funding was received for this article.

### Conflicts of interest

Drs. Erica Sakamoto, Marcus Fernando Kodama Pertille Ramos, Marina Pereira, Andre Roncon Dias, Ulysses Ribeiro Junior, Bruno Zilberstein and Sergio Carlos Nahas have no conflicts of interest or financial ties to disclose.

### Availability of data and material

All data generated or analysed during this study are included in this published article and its supplementary information files.

### Author's Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Erica Sakamoto, Marcus Fernando Kodama Pertille Ramos and Marina Alessandra Pereira. The first draft of the manuscript was written by Erica Sakamoto and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Ethics approval:** The study was approved by the Hospital's Ethics Committee and registered online (<https://plataformabrasil.saude.gov.br>, CAAE 25512819.1.0000.0065).

## References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68:394–424 . <https://doi.org/10.3322/caac.21492>
2. Ramos MFKP, Pereira MA, Yagi OK, Dias AR, Charruf AZ, Oliveira RJ de, Zaidan EP, Zilberstein B, Ribeiro-Júnior U, Cecconello I (2018) Surgical treatment of gastric cancer: a 10-year experience in a

- high-volume university hospital. *Clinics* 73:e543s . <https://doi.org/10.6061/clinics/2018/e543s>
3. Ji L, Selleck MJ, Morgan JW, Xu J, Babcock BD, Shavlik D, Wall NR, Langridge WH, Lum SS, Garberoglio CA, Reeves ME, Solomon N, Namm JP, Senthil M (2020) Gastric Cancer Peritoneal Carcinomatosis Risk Score. *Ann Surg Oncol* 27:240–247 . <https://doi.org/10.1245/s10434-019-07624-0>
  4. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. *International journal of cancer* 134:622–628
  5. Burbidge S, Mahady K, Naik K (2013) The role of CT and staging laparoscopy in the staging of gastric cancer. *Clin Radiol* 68:251–255
  6. **Kwee RM, Kwee TC** (2015) Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. *World J Gastroenterol* 21:10502–10509 . <https://doi.org/10.3748/wjg.v21.i37.10502>
  7. **Fujitani K, Yang H-K**, Mizusawa J, Kim Y-W, Terashima M, Han S-U, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang Y-J, Park BJ, Sasako M, Tsujinaka T (2016) Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. *Lancet Oncol* 17:309–318 . [https://doi.org/10.1016/S1470-2045\(15\)00553-7](https://doi.org/10.1016/S1470-2045(15)00553-7)
  8. Fukagawa T (2019) Role of staging laparoscopy for gastric cancer patients. *Ann Gastroenterol Surg* 3:496–505 . <https://doi.org/10.1002/ags3.12283>
  9. Gross E, Bancewicz J, Ingram G (1984) Assessment of gastric cancer by laparoscopy. *BMJ* 288:1577–1577
  10. Burke EC, Karpeh MS, Conlon KC, Brennan MF (1997) Laparoscopy in the management of gastric adenocarcinoma. *Ann Surg* 225:262–267 . <https://doi.org/10.1097/00000658-199703000-00004>
  11. Song KY, Kim JJ, Kim SN, Park CH (2007) Staging Laparoscopy for Advanced Gastric Cancer: Is It Also Useful for the Group Which has an Aggressive Surgical Strategy? *World Journal of Surgery* 31:1230–1235
  12. Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S, Yamaguchi T (2018) Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. *Surg Endosc* 32:268–275 . <https://doi.org/10.1007/s00464-017-5673-z>
  13. **Hu Y-F, Deng Z-W**, Liu H, Mou T-Y, Chen T, Lu X, Wang D, Yu J, Li G-X (2016) Staging laparoscopy improves treatment decision-making for advanced gastric cancer. *World J Gastroenterol* 22:1859–1868 . <https://doi.org/10.3748/wjg.v22.i5.1859>
  14. Nakamura N, Kinami S, Fujii Y, Miura S, Fujita J, Kaida D, Tomita Y, Miyata T, Fujita H, Ueda N, Iida Y, Kosaka T (2019) The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. *World J Surg Oncol* 17:108 . <https://doi.org/10.1186/s12957-019-1651-3>

15. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40:373–383 . [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8)
16. Doyle DJ, Goyal A, Bansal P, Garmon EH (2020) American Society of Anesthesiologists Classification (ASA Class). *StatPearls*. Treasure Island (FL)
17. Lee MH, Choi D, Park MJ, Lee MW (2012) Gastric cancer: imaging and staging with MDCT based on the 7th AJCC guidelines. *Abdom Imaging* 37:531–540 . <https://doi.org/10.1007/s00261-011-9780-3>
18. Kim JW, Shin SS, Heo SH, Choi YD, Lim HS, Park YK, Park CH, Jeong YY, Kang HK (2012) Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. *European Radiology* 22:654–662
19. Almeida MFA, Verza L, Bitencourt AGV, Boaventura CS, Barbosa PNVP, Chojniak R (2018) Computed tomography with a stomach protocol and virtual gastroscopy in the staging of gastric cancer: an initial experience. *Radiol Bras* 51:211–217 . <https://doi.org/10.1590/0100-3984.2017.0097>
20. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA: A Cancer Journal for Clinicians* 67:93–99
21. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. *Biometrics* 33:159–174
22. Karanicolas PJ, Elkin EB, Jacks LM, Atoria CL, Strong VE, Brennan MF, Coit DG (2011) Staging laparoscopy in the management of gastric cancer: a population-based analysis. *J Am Coll Surg* 213:644–651, 651.e1 . <https://doi.org/10.1016/j.jamcollsurg.2011.07.018>
23. Groh EM, Gupta S, Brown ZJ, Enewold L, Gamble LA, Hernandez JM, Davis JL (2020) Staging Laparoscopy is Underutilized in the Management of Gastric Adenocarcinoma. *Ann Surg Oncol* 27:1473–1479 . <https://doi.org/10.1245/s10434-019-08077-1>
24. Blakely AM, Miner TJ (2013) Surgical Considerations in the Treatment of Gastric Cancer. *Gastroenterol Clin North Am* 42:337–357 . <https://doi.org/10.1016/j.gtc.2013.01.010>
25. Leake P-A, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Law C, Coburn NG (2012) A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. *Gastric Cancer* 15 Suppl 1:S38–47 . <https://doi.org/10.1007/s10120-011-0047-z>
26. Bintintan VV, Cordoæ A, Chira R, Cocu S, Rus P, Bintintan A, Nagy G, Ciule L, Cata E, Pop A, Others (2018) The Value of Staging Laparoscopy for Optimal Multidisciplinary Treatment in Patients with Gastric Cancer. *Chirurgia* 113:789–798
27. Barchi LC, Ramos MFKP, Dias AR, Andreollo NA, Weston AC, Lourenço LG, Malheiros CA, Kassab P, Zilberstein B, Ferraz ÁAB, Charruf AZ, Brandalise A, Silva AM da, Alves B, Marins CAM, Leite CV, Bresciani CJC, Szor D, Mucerino DR, Consensus (2020) II BRAZILIAN CONSENSUS ON GASTRIC

CANCER BY THE BRAZILIAN GASTRIC CANCER ASSOCIATION. *Arq Bras Cir Dig* 33:e1514 .

<https://doi.org/10.1590/0102-672020190001e1514>

28. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, ESMO Guidelines Committee (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 27:v38–v49 . <https://doi.org/10.1093/annonc/mdw350>
29. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Michael Korn W, Craig Lockhart A, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H (2013) Gastric Cancer, Version 2.2013. *J Natl Compr Canc Netw* 11:531–546 . <https://doi.org/10.6004/jnccn.2013.0070>
30. Nassour I, Fullington H, Hynan LS, Yopp AC, Augustine MM, Polanco PM, Choti MA, Mansour JC, Wang SC, Porembka MR (2017) The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation. *Ann Surg Oncol* 24:1787–1794 . <https://doi.org/10.1245/s10434-017-5805-7>
31. Tsuchida K, Yoshikawa T, Tsuburaya A, Cho H, Kobayashi O (2011) Indications for staging laparoscopy in clinical T4M0 gastric cancer. *World J Surg* 35:2703–2709 . <https://doi.org/10.1007/s00268-011-1290-5>
32. Hosogi H, Shinohara H, Tsunoda S, Hisamori S, Sumida H, Hida K, Obama K, Okabe H, Sakai Y (2017) Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors. *Langenbecks Arch Surg* 402:33–39 . <https://doi.org/10.1007/s00423-016-1536-7>
33. Miki Y, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M (2015) Staging Laparoscopy for Patients with cM0, Type 4, and Large Type 3 Gastric Cancer. *World J Surg* 39:2742–2747 . <https://doi.org/10.1007/s00268-015-3144-z>
34. Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH (2010) Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. *J Surg Oncol* 102:753–757 . <https://doi.org/10.1002/jso.21685>
35. Machairas N, Charalampoudis P, Molmenti EP, Kykalos S, Tsaparas P, Stamopoulos P, Sotiropoulos GC (2017) The value of staging laparoscopy in gastric cancer. *Ann Gastroenterol Hepatol* 30:287–294 . <https://doi.org/10.20524/aog.2017.0133>
36. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS (2006) Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg* 191:134–138 . <https://doi.org/10.1016/j.amjsurg.2005.10.015>
37. Li K, Cannon JGD, Jiang SY, Sambare TD, Owens DK, Bendavid E, Poultsides GA (2018) Diagnostic staging laparoscopy in gastric cancer treatment: A cost-effectiveness analysis. *Journal of Surgical Oncology* 117:1288–1296

38. Munasinghe A, Kazi W, Taniere P, Hallissey MT, Alderson D, Tucker O (2013) The incremental benefit of two quadrant lavage for peritoneal cytology at staging laparoscopy for oesophagogastric adenocarcinoma. *Surg Endosc* 27:4049–4053 . <https://doi.org/10.1007/s00464-013-3058-5>
39. Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K (2007) Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. *Br J Cancer* 97:550–556 . <https://doi.org/10.1038/sj.bjc.6603909>
40. Takahashi H, Akita H, Wada H, Tomokuni A, Asukai K, Takahashi Y, Yanagimoto Y, Matsunaga T, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Yamamoto T, Nakanishi M, Shirayanagi M, Yamasaki T, Ohue M, Yano M, Sakon M, Ishikawa O (2018) Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. *Surgery* 164:1168–1177 . <https://doi.org/10.1016/j.surg.2018.06.047>
41. Kobayashi D, Kodera Y (2017) Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. *Gastric Cancer* 20:111–121 . <https://doi.org/10.1007/s10120-016-0662-9>
42. Macrì A, Morabito F (2019) The use of intraperitoneal chemotherapy for gastric malignancies. *Expert Rev Anticancer Ther* 19:879–888 . <https://doi.org/10.1080/14737140.2019.1671189>
43. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Nishikawa T, Tanaka J, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kazama S, Ishihara S, Sunami E, Watanabe T (2016) A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report. *Journal of Medical Case Reports* 10
44. Noma T, Takahashi T, Miyazaki Y, Kurokawa Y, Tanaka K, Makino T, Nakajima K, Yamasaki M, Mori M, Doki Y (2019) [Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases]. *Gan To Kagaku Ryoho* 46:184–186

## Tables

Table 1. clinical characteristics of GC patients according to the diagnosis of carcinomatosis by SL

Variables		P0 SL	P1 SL	<i>p</i>
		<b>n = 64 (%)</b>	<b>n = 66 (%)</b>	
<b>Sex</b>				0.553
	Female	22 (34.4)	26 (39.4)	
	Male	42 (65.6)	40 (60.6)	
<b>Age (years)</b>				0.092
	Mean (SD)	61.6 (11.9)	57.5 (15.3)	
<b>BMI (Kg/m<sup>2</sup>)</b>				0.719
	Mean (SD)	22.6 (4.8)	22.3 (4.8)	
<b>Albumin (g/dL)</b>				0.100
	Mean (SD)	3.8 (0.5)	3.6 (0.6)	
<b>Hemoglobin (g/dL)</b>				0.291
	Mean (SD)	10.9 (2.1)	11.4 (2.1)	
<b>Charlson–Deyo Comorbidity Index (CCI)</b>				0.761
	0	47 (73.4)	50 (75.8)	
	≥1	17 (26.6)	16 (24.2)	
<b>ASA (American Society of Anesthesiologists)</b>				0.538
	I/II	44 (68.8)	42 (63.6)	
	III/IV	20 (31.2)	24 (36.4)	
<b>Circumferential lesion</b>				<b>0.005</b>
	Yes	28 (43.8)	45 (68.2)	
	No	36 (56.2)	21 (31.8)	

<b>Tumor size (cm)</b>			0.210
	Mean (SD)	7.0 (3.2)	7.8 (3.4)
<b><i>Linitis plastica</i></b>			<b>0.001</b>
	Absent	61 (95.3)	49 (74.2)
	Present	3 (4.7)	17 (25.8)
<b>Tumor site</b>			<b>0.004</b>
	Antrum / Body	44 (68.8)	36 (54.6)
	Fundus / cardia	18 (28.1)	15 (22.7)
	Whole organ	2 (3.1)	15 (22.7)
<b>Lauren type</b>			<b>0.001</b>
	Intestinal	31 (48.4)	11 (16.7)
	Diffuse/mixed	29 (45.3)	50 (75.8)
	Adenocarcinoma (not specified)	4 (6.2)	5 (7.6)
<b>Macroscopic Type</b>			<b>0.001</b>
	I	2 (3.1)	0 (0)
	II	6 (9.4)	2 (3)
	III	49 (76.6)	39 (59.1)
	IV	6 (9.4)	21 (31.8)
	V	1 (1.6)	4 (6.1)

Table 2. CT diagnosis and outcomes of GC patients according to the diagnosis of carcinomatosis by SL

<b>Variables</b>	<b>P0 SL</b>	<b>P1 SL</b>	<b><i>p</i></b>
	<b>n = 64 (%)</b>	<b>n = 66 (%)</b>	
<b>Presence of Ascites on CT</b>			<b>&lt;0.001</b>
Absent	51 (79.7)	20 (30.3)	
Present	13 (20.3)	46 (69.7)	
<b>Peritoneal lesions on CT</b>			<b>&lt;0.001</b>
No	56 (87.5)	32 (48.5)	
Yes	8 (12.5)	34 (51.5)	
<b>Liver metastasis on CT</b>			0.496
No	64 (100)	64 (97)	
Yes	0 (0)	2 (3)	
<b>cT</b>			0.147
≤cT3	17 (26.6)	9 (13.6)	
cT4a	27 (42.2)	29 (43.9)	
cT4b	20 (31.2)	28 (42.4)	
<b>cN</b>			0.861
cN0	9 (14.1)	10 (15.2)	
cN+	55 (85.9)	56 (84.8)	
<b>cM</b>			<b>&lt;0.001</b>
M0	56 (87.5)	28 (42.4)	
M1	8 (12.5)	38 (57.6)	
<b>cTNM</b>			<b>&lt;0.001</b>
≤II	10 (15.6)	4 (6.1)	
III / IVA	46 (71.9)	23 (34.8)	
IVB	8 (12.5)	39 (59.1)	

Table 3. Comparison between SL and CT staging for carcinomatosis (P1)

Group	P1 SL	P0 SL	Total	Predictive values
P1 CT	34	8	42	34 of 42 - PPV 81.0%
P0 CT	32	56	88	56 of 88 - NPV 63.6%
<b>Total</b>	<b>66</b>	<b>64</b>	<b>130</b>	
	Sensitivity - 34 of 66 (51.5%)	Specificity - 56 of 64 (87.5%)		Accuracy 90 of 130 (69.2%)
SL= staging laparoscopy; CT= computed tomography; P1= peritoneal metastasis; PPV= positive predictive value; NPV= negative predictive value				

Table 4. Univariate and multivariate analysis of factors associated with the diagnosis of carcinomatosis by SL (P1 group)

Variables*	Univariate			Multivariate		
	OR	95% CI	<i>p</i>	OR	95% CI	<i>p</i>
Age ≥ 65 (vs <65 years)	0.89	0.44 - 1.79	0.746	–	–	–
Male (vs female)	0.81	0.39 - 1.65	0.554	–	–	–
Proximal/whole (vs antrum/body)	1.81	0.89 - 3.75	0.098	–	–	–
Circumferential (vs non-circumferential)	2.75	1.35 - 5.64	<b>0.006</b>	1.06	0.42 - 2.67	0.898
<i>Linitis plastica</i> (vs absent)	7.05	1.95 - 25.47	<b>0.003</b>	3.21	0.70 - 14.65	0.132
cT4 (vs others)	2.29	0.94 - 5.61	0,070	–	–	–
cN+ (vs cN0)	0.92	0.35 - 2.43	0,861	–	–	–
P1 CT (vs P0)	7.44	3.07 - 18.01	<b>&lt;0.001</b>	3.96	1.45 - 10.81	<b>0.007</b>
Ascites (vs absent)	9.02	4.04 - 20.16	<b>&lt;0.001</b>	4.94	1.98 - 12.35	<b>0.001</b>
Diffuse/mixed (vs other)	3.77	1.79 - 7.97	<b>0.001</b>	2.45	0.99 - 6.05	0.052
OR= odds ratio; CI= confidence interval; P= Peritoneum; CT= computed tomography						

# Figures



Figure 1

SL with macroscopic carcinomatosis. (a) gross peritoneal spread. (b) single node




Figure 2

Change in treatment strategy after SL




Figure 3

Overall survival for GC patients according to the M status by CT and SL